{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:48:34Z","timestamp":1774673314627,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40266-025-01192-7","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T02:05:52Z","timestamp":1743559552000},"page":"469-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Benefit\u2013Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-7168","authenticated-orcid":false,"given":"Paul P.","family":"Dobesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert A.","family":"Volkl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1kos Ferenc","family":"Pap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. V.","family":"Damaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpesh N.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"1","key":"1192_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1\u2013156.","journal-title":"Circulation"},{"key":"1192_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42:373\u2013498.","journal-title":"Eur Heart J"},{"issue":"6","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545\u2013608.","journal-title":"Chest"},{"issue":"19","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693\u2013738.","journal-title":"Blood Adv"},{"issue":"4","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603.","journal-title":"Eur Heart J"},{"issue":"4","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ahj.2004.11.015","volume":"149","author":"JP DiMarco","year":"2005","unstructured":"DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(4):650\u20136.","journal-title":"Am Heart J"},{"issue":"2","key":"1192_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130(2):138\u201346.","journal-title":"Circulation"},{"issue":"1","key":"1192_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-9560-11-21","volume":"11","author":"MH Prins","year":"2013","unstructured":"Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.","journal-title":"Thromb J"},{"issue":"3","key":"1192_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022478","volume":"9","author":"M Rohla","year":"2019","unstructured":"Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational prevention of thromboembolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9(3): e022478.","journal-title":"BMJ Open"},{"issue":"5","key":"1192_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","volume":"5","author":"ET Kato","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(5): e003432.","journal-title":"J Am Heart Assoc"},{"issue":"28","key":"1192_CR11","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864\u201372.","journal-title":"Eur Heart J"},{"issue":"8","key":"1192_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256338","volume":"16","author":"SW Reinhardt","year":"2021","unstructured":"Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: a secondary analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. PLoS ONE. 2021;16(8): e0256338.","journal-title":"PLoS ONE"},{"issue":"11","key":"1192_CR13","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1111\/jth.15477","volume":"19","author":"W Ageno","year":"2021","unstructured":"Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott GC, et al. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021;19(11):2772\u201380.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1192_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"12","key":"1192_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017157","volume":"7","author":"KAA Fox","year":"2017","unstructured":"Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12): e017157.","journal-title":"BMJ Open"},{"issue":"3","key":"1192_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000250","volume":"2","author":"DE Singer","year":"2013","unstructured":"Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3): e000250.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1192_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"46","key":"1192_CR18","first-page":"3258","volume":"36","author":"EC O'Brien","year":"2015","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258\u201364.","journal-title":"Eur Heart J"},{"issue":"3","key":"1192_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","volume":"151","author":"BF Gage","year":"2006","unstructured":"Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713\u20139.","journal-title":"Am Heart J"},{"issue":"10","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/jth.14253","volume":"16","author":"G Palareti","year":"2018","unstructured":"Palareti G, Antonucci E, Mastroiacovo D, Ageno W, Pengo V, Poli D, et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. J Thromb Haemost. 2018;16(10):1994\u20132002.","journal-title":"J Thromb Haemost"},{"key":"1192_CR21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/s-2007-1002635","volume":"17","author":"JA Caprini","year":"1991","unstructured":"Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17:304\u201312.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"1192_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jth.12108","volume":"11","author":"M Vardi","year":"2013","unstructured":"Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost. 2013;11(3):467\u201373.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1192_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1378\/chest.10-1944","volume":"140","author":"AC Spyropoulos","year":"2011","unstructured":"Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706\u201314.","journal-title":"Chest"},{"issue":"1","key":"1192_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","volume":"100","author":"N Ruiz-Gimenez","year":"2008","unstructured":"Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26\u201331.","journal-title":"Thromb Haemost"},{"issue":"8","key":"1192_CR25","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/jth.15776","volume":"20","author":"PL den Exter","year":"2022","unstructured":"den Exter PL, Woller SC, Robert-Ebadi H, Masias C, Morange PE, Castelli D, et al. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC subcommittee on predictive and diagnostic variables in thrombotic disease. J Thromb Haemost. 2022;20(8):1910\u20139.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/eurjpc\/zwab088","volume":"29","author":"L Mazzolai","year":"2022","unstructured":"Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2022;29(8):1248\u201363.","journal-title":"Eur J Prev Cardiol"},{"key":"1192_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-9560-12-25","volume":"12","author":"RM Bauersachs","year":"2014","unstructured":"Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, et al. Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12:25.","journal-title":"Thromb J"},{"issue":"1","key":"1192_CR28","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37-46.","journal-title":"Lancet Haematol"},{"issue":"13","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","volume":"132","author":"G Patti","year":"2019","unstructured":"Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749-57.e5.","journal-title":"Am J Med"},{"issue":"2","key":"1192_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacc.2018.04.055","volume":"72","author":"CM Gibson","year":"2018","unstructured":"Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, et al. Fatal or irreversible bleeding and ischemic events with rivaroxaban in acute coronary syndrome. J Am Coll Cardiol. 2018;72(2):129\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1192_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"key":"1192_CR33","doi-asserted-by":"crossref","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"1192_CR34","doi-asserted-by":"crossref","unstructured":"EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287\u201397.","DOI":"10.1056\/NEJMoa1113572"},{"key":"1192_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.thromres.2018.06.009","volume":"168","author":"P Prandoni","year":"2018","unstructured":"Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res. 2018;168:121\u20139.","journal-title":"Thromb Res"},{"issue":"5","key":"1192_CR36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.chest.2016.05.023","volume":"150","author":"PS Wells","year":"2016","unstructured":"Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, et al. Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: a benefit-risk analysis of EINSTEIN-Extension. Chest. 2016;150(5):1059\u201368.","journal-title":"Chest"},{"issue":"20","key":"1192_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026229","volume":"11","author":"GE Raskob","year":"2022","unstructured":"Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, et al. Benefit-risk assessment of rivaroxaban for extended thromboprophylaxis after hospitalization for medical illness. J Am Heart Assoc. 2022;11(20): e026229.","journal-title":"J Am Heart Assoc"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/VHRM.S54714","volume":"10","author":"B Levitan","year":"2014","unstructured":"Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manage. 2014;10:157\u201367.","journal-title":"Vasc Health Risk Manage"},{"issue":"8","key":"1192_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032782","volume":"13","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs RM, Berkowitz SD, et al. Quantitative benefit-risk evaluation of rivaroxaban in patients after peripheral arterial revascularization: the VOYAGER PAD trial. J Am Heart Assoc. 2024;13(8): e032782.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"1192_CR40","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMp0907122","volume":"361","author":"EF Unger","year":"2009","unstructured":"Unger EF. Weighing benefits and risks\u2014the FDA\u2019s review of prasugrel. N Engl J Med. 2009;361(10):942\u20135.","journal-title":"N Engl J Med"},{"issue":"19","key":"1192_CR41","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1056\/NEJMp1103050","volume":"364","author":"BN Beasley","year":"2011","unstructured":"Beasley BN, Unger EF, Temple R. Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"1192_CR42","first-page":"67","volume":"19","author":"I Cavallari","year":"2018","unstructured":"Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018;19(1):67\u201371.","journal-title":"Anatol J Cardiol"},{"key":"1192_CR43","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of subgroups in confirmatory clinical trials. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf. Accessed 10 Mar 2025."},{"issue":"5","key":"1192_CR44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","volume":"151","author":"FA Anderson Jr","year":"1991","unstructured":"Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933\u20138.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1192_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/archinte.1994.00420080053005","volume":"154","author":"WD Kniffin Jr","year":"1994","unstructured":"Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154(8):861\u20136.","journal-title":"Arch Intern Med"},{"issue":"9","key":"1192_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/03007995.2023.2247988","volume":"39","author":"WL Baker","year":"2023","unstructured":"Baker WL, Roberts MS, Bessada Y, Caroti KS, Ashton V, Bookhart BK, et al. Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies. Curr Med Res Opin. 2023;39(9):1183\u201394.","journal-title":"Curr Med Res Opin"},{"key":"1192_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5651","volume":"351","author":"JF Burke","year":"2015","unstructured":"Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351: h5651.","journal-title":"BMJ"},{"key":"1192_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2017.06.110","volume":"257","author":"AS Barnett","year":"2018","unstructured":"Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, et al. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF. Int J Cardiol. 2018;257:78\u201383.","journal-title":"Int J Cardiol"},{"issue":"11","key":"1192_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.006212","volume":"12","author":"SJ Shah","year":"2019","unstructured":"Shah SJ, Singer DE, Fang MC, Reynolds K, Go AS, Eckman MH. Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2019;12(11): e006212.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1192_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s12872-023-03643-8","volume":"23","author":"K Methavigul","year":"2023","unstructured":"Methavigul K, Chichareon P, Yindeengam A, Krittayaphong R. Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA(2)DS(2)-VASc score. BMC Cardiovasc Disord. 2023;23(1):623.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"1192_CR51","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.10.001","volume":"23","author":"S Uchiyama","year":"2014","unstructured":"Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, et al. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2014;23(5):1142\u20137.","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01192-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:03:38Z","timestamp":1746453818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01192-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01192-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen Scientific Affairs, LLC, a Johnson & Johnson Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.P.D. has served as a consultant for the Pfizer\/Bristol Myers Squibb alliance, Janssen Pharmaceuticals, and AstraZeneca. \u00c1.F.P. is an employee of Bayer AG. A.A.V., C.D., B.L., and Z.Y. are employees of Johnson and Johnson. A.N.A. has served as principal investigator or coinvestigator of clinical trials sponsored by NIH\/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, and Alexion; speaker and\/or consultant for Pfizer, BMS, Jansen, Portola, Salix, Alexion, AstraZeneca, Bayer, Ferring, Seres, Spero, Eli Lilly, Nova Nordisk, Gilead, Renibus, GSK, Dexcom, Reprieve, HeartRite, and Aseptiscope; unrelated to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson and Johnson (J&J) is available at . The data supporting the findings of this study may be obtained from the authors, if the request is approvable per the J&J data sharing policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}